18 results about "Pancreatic duct" patented technology

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The invention discloses a self-breaking outer drainage tube, and relates to the technical field of medical instruments, the self-breaking outer drainage tube comprises a tube body, and the tube body comprises a drainage part, a breaking part, a leading-out part and a puncture part; the drainage part and the fracture part are both made of degradable materials; the hole wall thickness of the circulation hole at the fracture part is smaller than the hole wall thickness of the circulation hole at the drainage part; during surgical operation, the degradable inner drainage part is placed in the pancreatic duct, the fracture part crosses the anastomotic stoma by 7-8 cm and crosses the biliary-intestinal anastomotic stoma, and the leading-out part walks in the enteric cavity to a proper position, penetrates out of the intestinal wall and is led out of the body through the abdominal wall. Cutting the puncture part to expose the outlet of the circulation hole, and discharging the body fluid through the circulation hole; after a certain period of time after the operation, the fracture part is automatically fractured under the action of pancreatic juice, the leading-out part is pulled out, the degradable drainage part continues to be degraded in the body and maintains the drainage function, and finally the drainage part is absorbed by the body or discharged out of the body without being taken out through the operation.

A medical image processing apparatus according to an embodiment includes processing circuitry. The processing circuitry is configured to obtain a medical image related to the pancreas. The processing circuitry is configured to extract a pancreas region included in the medical image. The processing circuitry is configured to extract at least one tubular structure region from the inside of the pancreas region. The processing circuitry is configured to identify a first end part and a second end part related to the pancreas on the basis of the pancreas region. The processing circuitry is configured to estimate a primary pancreatic duct centerline of the pancreas on the basis of the tubular structure region, the first end part, and the second end part.

The utility model belongs to the technical field of drainage tubes, and particularly relates to a pancreatic duct supporting drainage tube for pancreatic surgery, which comprises a drainage main tube and a sleeve, one end of the drainage main tube is detachably connected with the sleeve through a first connecting component, a supporting component is arranged in the drainage main tube, a fixing component is arranged on the sleeve, and the fixing component is detachably connected with the sleeve through a second connecting component. The fixing assembly and the supporting assembly are detachably connected together through the second connecting assembly. The first connecting assembly comprises a first annular plate, the first annular plate is fixedly installed at one end of the drainage main pipe, and a first annular groove is formed in the left side of the sleeve. The supporting assembly is arranged in the drainage main pipe, and the fixing assembly is arranged on the sleeve, so that when the pancreas surgery is carried out, the drainage main pipe can be prevented from being flattened, the position of the sleeve can be fixed, and the situation that the drainage main pipe is blocked due to extrusion can be avoided.

The invention belongs to the field of biomedical materials, and particularly relates to an inner drainage end-by-end reducer tube based on the electrostatic spinning technology and a preparation method thereof.The inner drainage end-by-end reducer tube comprises an end-by-end reducing drainage tube, the whole drainage tube is of a hollow conical tubular structure, and the surface of the drainage tube is provided with regularly-arranged thread structures; the invention further provides a preparation method of the inner drainage end-by-end reducer pipe. The defects of existing internal drainage are overcome, and the natural anatomical form of the pancreatic duct is complied with by means of the drainage tube with the diameter changed end by end; the drainage tube is provided with a surface thread structure, and by matching with the swelling characteristic of a biodegradable material, the friction force between the drainage tube and the pancreatic duct wall is increased, and the probability of displacement of the drainage tube due to intestinal tract movement or pancreatic juice scouring is reduced.

This invention provides a single-operated duodenal sphincter cutter, comprising: an outer sheath, a guidewire, a metal wire, and a handle. The guidewire is inserted into the interior of the outer sheath through its wall and exits from its tip. The handle is connected to the tail of the outer sheath. One end of the metal wire is fixedly connected to the front of the outer sheath, and the other end is inserted into the interior of the outer sheath and connected to the handle. This invention features a dual-channel tube, with the guidewire entering the guidewire channel through the side wall. Its outer diameter is thinner than that of a conventional three-channel tube. The guidewire is led out through the side wall of the tube. With the outer sheath fixed in place, the operator can insert the guidewire into the common bile duct or pancreatic duct without the assistance of an assistant, increasing the success rate of cannulation.

[Problem] To provide: a cannula that can be easily inserted into a common bile duct or a pancreatic duct via a major duodenal papilla; and an endoscopic system provided with such a cannula. [Solution] A second camera 30 of a cannula 12 captures an image of the entrance of a common bile duct or a pancreatic duct in a state where the second camera 30 is inserted from the opening of a major duodenal papilla. A transparent shield 124 provides a cavity around the second camera 30 and ensures a field of view Vf of the second camera 30 in a state where the transparent shield 124 is inserted from the opening. The shield 124 has a convex surface 124c around the central axis CA of the field of view Vf of the second camera 30. The portion having the convex surface 124c has a uniform thickness. A guide wire 15 is configured to advance within the field of view Vf of the second camera 30.

The invention discloses an application of miR-100 sponge in preparation of a medicine for treating type 2 diabetes mellitus. The miR-100 sponge can inhibit miR-100 in a targeted manner and close the expression of miR-100 in beta cells. The nucleic acid construct is further prepared from the nucleic acid construct, AAV8-mmu-miR-100 Sponge (AAV-Sponge) is injected into pancreatic ducts of obese diabetes mellitus mice, after treatment is conducted for 4 weeks, it is found that the sugar tolerance of the mice in a treatment group is improved, the GSIS function of beta cells is improved, and the nucleic acid construct is expected to be further applied to preparation of the medicine for treating the type 2 diabetes mellitus. The problems that current treatment methods for type 2 diabetes mellitus are deficient and the treatment cost is high are solved.

Systems and methods for treating, for example, strictures along a biliary tract and / or pancreatic duct are disclosed. An example system can include a handle (14) having a base, a first carriage (26) translatable relative to the base, and a second carriage (24) translatable relative to the base. A sheath (16) can be coupled to the first carriage. The system can also include a catheter shaft (12) having a proximal region and a steerable distal region. The proximal region can be coupled to the second carriage. A needle can be releasably coupled to the handle. The needle can be configured to pass through tissue to a location along a biliary tract and / or pancreatic duct. The system can also include a steering member (44) having a first end coupled to the steerable distal region of the catheter shaft and a second end disposed adjacent the handle.

The utility model relates to medical instrument technical field especially, and it is a kind of covered stent and implantation system.This covered stent includes support framework and film, wherein: support framework is the hollowed out cylinder structure of peripheral surface, it can be radially compressed and expand;Film is coated on part support framework, and drainage mesh is formed at the region of support framework not being coated by film.Due to film being coated on part support framework, drainage mesh is formed at the region of support framework not being coated by film, bile of gallbladder, bile in common hepatic duct and pancreatic juice in pancreatic duct can enter the inside of covered stent through drainage mesh and reach duodenal papilla, thereby avoiding the phenomenon that bile and pancreatic juice cannot flow out from common bile duct and reach duodenal papilla due to common bile duct being pressed by stent, and simultaneously, a plastic stent does not need to be additionally implanted in common bile duct to help common bile duct drainage, to achieve the purpose of reducing operation cost and operation complexity.

The utility model provides a kind of wire guide calculus extraction net basket, including net basket, guide wire, net basket cap, outer sheath and handle, tail end of guide wire is connected with the head end of net basket cap, net basket cap is placed in the head end outside of outer sheath, net basket is inserted to the inside of outer sheath through the tail end of outer sheath, one end of net basket is connected with the tail end of net basket cap, other end is connected with handle;Handle is located in the tail end outside of outer sheath.The utility model can be inserted through papilla incision knife, SpyGlass or insight pancreatic duct imaging system channel etc.Various instrument channels, realize the calculus extraction treatment of multiple scenes;During the release of net basket, soft guide wire head end crosses stone more easily into the distal bile duct, more conducive to the release of net basket, and net basket can be taken out of stone by pulling back.

An amplifying method of pancreatic cells is provided. The amplifying method includes performing digestion, resuspension, discontinuous density gradient centrifugation treatment and amplifying treatment sequentially. The mammalian pancreatic duct is used as the source of pancreatic precursor-like cells in the amplifying method, and islet cells and acinar cells in the cell clusters obtained by the discontinuous density gradient centrifugation treatment are removed. It is beneficial to improve the yield of the pancreatic precursor-like cells availably, and avoid the ethical restrictions and possible carcinogenic risks caused by using the embryonic stem cells. The amplifying medium used comprises a reprogramming substance composed of several small molecule compounds. It can avoid the risks of non-specific and off-target deletion that are easily caused by the use of the gene-editing methods to change the gene sequence. Also provided is a differentiation method and an application of the pancreatic precursor-like cells obtained by the amplifying method.

The invention relates to the technical field of magnetic resonance imaging, and discloses a thin-layer oblique coronal focusing view diffusion weighted imaging method of a magnetic resonance system, which comprises the following steps of: extracting a three-dimensional space walking path of a target bile duct based on magnetic resonance pancreaticobiliary duct water imaging and a cross section T2 weighted image, performing optimal plane fitting, and determining a personalized oblique coronal scanning plane; in the plane, diffusion weighted imaging is carried out by adopting a small visual field set according to bile duct projection, a layer thickness not higher than 3.0 mm and a low b value not higher than 100 seconds / square millimeters and a high b value not lower than 800 seconds / square millimeters, and echo time is set to a minimum value allowed by a system. Through cooperation of personalized plane positioning, thin-layer high-b-value imaging and intelligent quality control, the problems that conventional magnetic resonance imaging is incomplete in display of an extrahepatic cholangiocarcinoma lesion anatomical structure, low in signal-to-noise ratio, multiple in motion artifacts and difficult to accurately evaluate the longitudinal infiltration range of a tumor are solved.

The invention relates to the technical field of biological medicines, in particular to application of a reagent for inhibiting expression of miR-758-3p in preparation of a medicine for treating pancreatic ductal adenocarcinoma. The reagent is a micro RNA (miRNA) inhibitor, a small interfering RNA (siRNA), an antisense oligonucleotide (ASO) or a combination of the micro RNA inhibitor, the small interfering RNA (siRNA) and the antisense oligonucleotide (ASO) which can down-regulate the expression of the miR-758-3p. The invention also relates to a medicine for treating pancreatic ductal adenocarcinoma, which comprises an effective amount of the reagent and a pharmaceutically acceptable carrier. The medicine is used for inhibiting proliferation, migration and / or invasion of pancreatic duct adenocarcinoma cells. The invention provides a new biomarker and a treatment intervention target for pancreatic ductal adenocarcinoma. And the feasibility of targeted therapy is defined. And the method has a definite conversion prospect.

This invention relates to a novel use of synephrine in the preparation of drugs for treating cholestatic liver disease, belonging to the field of pharmaceutical technology. Cholestatic liver disease is characterized by jaundice and conjugated bilirubin and / or total bilirubin hyperconjugation caused by impaired bilirubin excretion due to various reasons. Its causes include common bile duct stones, pancreatic duct cancer, common bile duct malignant tumors, pancreatic cancer, biliary parasitic diseases, viral hepatitis cirrhosis, alcoholic liver disease, fatty liver disease, drug-induced liver injury, primary biliary cirrhosis, intrahepatic sclerosing cholangitis, and certain congenital diseases such as Dubin-Johnson syndrome and Rotor syndrome. This invention establishes a mouse cholestasis model using bile duct ligation and administers synephrine by gavage to evaluate its protective effect against liver injury. The results showed that synephrine significantly improved jaundice caused by cholestasis, reduced hepatocellular necrosis and inflammatory infiltration caused by cholestasis, alleviated bile duct dilation, decreased serum total bilirubin (TBIL) and direct bilirubin (DBIL), and reduced the levels of total bile acids (BA) in liver tissue and plasma. Furthermore, the above-mentioned effects of synephrine in improving cholestasis showed a clear dose-dependent effect. This invention reveals for the first time the application of synephrine in cholestatic liver disease, demonstrating good safety and promising clinical development prospects.

The invention discloses a pancreatic fistula risk assessment system after pancreaticoduodenectomy based on multi-factor analysis, and relates to the technical field of medical information. Comprising a data acquisition module which is used for acquiring preoperative CT images and clinical data of a patient; the feature extraction module is used for quantitatively extracting radiomics features, pancreatic duct diameters and body component indexes from the CT images; the model construction module is used for integrating the features through multivariable logistic regression to construct a prediction model; the verification module is used for resampling through a self-service method and evaluating the performance of the model through an ROC curve; and an output module. According to the method, through multi-factor integration, the accuracy of CR-POPF preoperative prediction is remarkably improved, and the method is superior to a single-index model; and subjective deviation is reduced based on objective data, and clinical availability is improved in a network calculator form.

The utility model provides a kind of double guide wire nipple sphincter incision knife, comprising: outer sheath, handle, first guide wire, second guide wire and wire, first guide wire is inserted to the inside of outer sheath through the pipe wall of outer sheath, and it is worn from the pipe wall of outer sheath;Handle is connected with the tail end of outer sheath, second guide wire is inserted to the inside of outer sheath through handle, and it is worn from the head end of outer sheath;One end of wire is fixedly connected on the pipe wall of outer sheath, the other end is inserted into the inside of outer sheath, and is connected with handle.The utility model uses, assistant can implement guide wire auxiliary nipple sphincter incision knife cannula into pancreatic duct, on the basis of not increasing nipple incision knife pipe diameter, operator can operate second guide wire and insert into common bile duct through pipe wall lateral wall, realize double person multi-angle cannulation, increase the success rate of bile duct cannulation.

The invention relates to the technical field of biological medicine, in particular to an MTA3 small-molecule inhibitor and application thereof in sensitizing chemotherapy effect of gemcitabine pancreatic duct adenocarcinoma. The invention provides a small molecule MTA3i-01 which is obtained through high-throughput virtual screening and structure optimization. The micromolecule MTA3i-01 provided by the invention can specifically interfere with the combination of the MTA3 protein and the CRIP2 gene promoter region, and effectively recover the sensitivity of tumor cells to gemcitabine, thereby significantly enhancing the curative effect of chemotherapy. The tumor growth can be obviously inhibited by the combined treatment of the MTA3i-01 and the gemcitabine, the tumor growth is obviously inhibited by the combined treatment of the MTA3i-01 and the gemcitabine, the combined treatment is obviously superior to that of a gemcitabine single drug group and a MTA3i-01 single drug group, and obvious toxic reaction is not observed, so that the combined scheme has good in-vivo safety and synergistic curative effect.